Effective control of breast cancer depends on three types of research accomplishment -- understanding the disease's origins and progression: successfully applying this knowledge to methods of detection, diagnosis and treatment: and finding ways to make these advances truly available to the public as effectively as possible. The significant progress that is occurring across this entire spectrum of pioneering investigation is reflected in these proceedings of the 1987 biennial conference of the International Association for Breast Cancer Research. The first section of the book focuses on oncogenes and chemical effectors that may play key roles in early cell transformation leading to breast cancer. Research discussed includes identification of specific oncogenes which appear to be involved in the disease, study of their activation and expression, examination of the biological effects of various growth factors isolated from breast cancer cell lines, and investigation of the molecular mechanisms by which estrogens promote and stimulate growth of breast cancers. The second group of chapters deals with several other complex factors and phenomena which may influence tumor formation in the breast, for example, expression of abnormalities by fibroblasts, disruption of epithelial-mesenchymal interactions, and loss of ability nili to synthesize normal basal lamina resulting in alterations in the extracellular matrix. Clarification of the processes of normal mammary gland development and differentiation is central to much of this work.

During the past four decades knowledge about biological effects of ionizing radiations on mammalian cells, normal tissues and tumours has increased enormously and has enabled radiotherapists to obtain a better insight into the advantages and disadvantages of cancer treatments with modified regimens of irradiations and combinations with chemotherapeutic agents. Even for the older scientists and clinicians who have wit nessed all these developments and have contributed to the vast amount of information, it is difficult to integrate this knowledge and to apply it in their daily work. For younger workers it is often difficult to select the important main concepts and results from the overwhelming number of publications. It is evident that a book which provides an integrated view of basic and applied radiation oncology can be of great value to students, scientists and, most importantly, to clinicians who can devote only part of their time to the task of understanding the radiobiological background of their application of radiation in cancer treatment. This book "Radiation Oncology" is written by a radiotherapist who has for a long time participated in the integration of basic knowledge and clinical experience. He has selected radiobiological information which is considered important to radiotherapy and in the description and interpretation of normal tissue tolerance and tumour eradication probability, he illustrates how basic knowledge can be applied clinically."

In recent years, there have been major advances in the treatment of patients with gynecologic malignancies. Perhaps the biggest advances have been in the area of ovarian cancer. Gynecologic Oncology focuses primarily upon this malignancy. This volume discusses cytoreductive surgery; screening for ovarian cancer; chemotherapy; new chemotherapeutic drugs; the controversy regarding the role of high-dose chemotherapy in gynecologic cancers; the hereditary basis for gynecologic malignancies; molecular genetics; molecular biology and new biologic therapies. Other topics covered are the treatment of all stages of cervical cancer, including radiotherapy. In addition, a chapter on advances in the pathology of gynecologic cancers is included. The advances made in the treatment of gynecologic malignancies are due, in part, to the clinical studies performed by many of the contributors to this volume. Clinical advances have been the result of multidisciplinary approaches which involve molecular biologists, pathologists, radiation therapists, surgeons and chemotherapists. Future advances will continue to rely upon collaborative interaction among these different disciplines.

Advances in genetics are transforming estimates of an individual 's risk of developing cancer and approaches to prevention and management of cancer in those who may have increased susceptibility. Identifying and caring for patients with hereditary cancer syndromes and their family members present a complex clinical, scientific and social challenge. This textbook, by leading experts at Massachusetts General Hospital Cancer Center, highlights the current understanding of the genetics of hereditary cancers of the breast, ovary, colorectum, stomach, pancreas, kidney, skin, and endocrine organs. Practical guidelines for the use of genetic testing, cancer screening and surveillance, prophylactic surgery, and promising targeted therapeutic agents are discussed.

In addition, ongoing research involving genome-wide screens to identify novel modest risk-associated genetic loci are explored, along with new approaches to the application of genetic markers in guiding therapeutic options.

Oxidation-reduction (i.e. redox) processes at the plasma membrane of any cell have been attracting more and more attention, both in basic and in applied research, since the first workshop dealing with the plasma membrane oxidoreductases was organized in Cordoba, Spain, in 1988. This evolution is evident considering the numerous cell functions performed by plasma membrane redox systems not only in healthy cells but also in cells that escaped from the normal metabolic control (e.g. cancer cells) and cells under attack by pathogens. Plasma membrane redox processes have now been demonstrated to play an essential role in growth control and defense mechanisms of these cells. The great importance of the plasma membrane redox systems originates in the fact that they are located in the membrane which is essentially the site of communication between the living cell and its environment. We may say that the plasma membrane can be considered as the "sensory part" of the cell. No chemical substance can enter the cell interior without interaction with the plasma membrane.

Since the discovery of microRNAs (miRNAs) some twenty years ago by Victor Ambros, David Baulcombe and Gary Ruvkun, these three scientists worked to uncover the mystery of miRNA, the small segments of nucleotides that silence genes. While studying the development of the nematode worm, Ambros and Ruvkun discovered miRNA in animals, while Baulcombe discovered it in plants. Since their discovery, it took more than two decade to fully appreciate the value of miRNA in human health and diseases. Emerging evidence suggest that the activation of oncogenes and/or the inactivation of tumor suppressor genes contribute to the development and progression of tumors. The regulation of genes is by far controlled by many transcription factors which are often deregulated during the development and progression of cancer. In addition, emerging evidence clearly suggests that the deregulation of miRNAs or small non-coding RNAs could also regulate the expression of genes, and likewise, miRNA genes are also regulated by transcription factors. The most attractive feature of miRNAs is that one miRNA can regulate many target genes (mRNAs), and thus miRNA targeted therapy is highly promising because multiple genes could be regulated by targeting a single miRNA, which becomes very important for the killing of highly heterogeneous populations of cancer cells within a tumor mass. Therefore, miRNA targeted therapy is an attractive attribute of miRNA research, which is covered through eighteen chapters complied in this book "MicroRNA targeted Cancer therapy," and it is hoped that the field of miRNA research will be appreciated through critical reading of these chapters on the cutting-edge research on miRNAs.

It has been generally accepted that angiogenesis is involved in the pathogenesis of hematological malignancies, like acute and chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms and multiple myeloma. The extent of angiogenesis in the bone marrow has been correlated with disease burden, prognosis and treatment outcome. Reciprocal positive and negative interactions between tumor cells and bone marrow stromal cells, namely hematopoietic stem cells, fibroblasts, osteoblasts/osteoclasts, endothelial cells, endothelial progenitor cells, T cells, macrophages and mast cells, mediated by an array of cytokines, receptors and adhesion molecules, modulate the angiogenic response in hematological tumors. More recently, it has been emphasized the pro-angiogenic role of the so called "vascular niche," indicating a site rich in blood vessels where endothelial cells and mural cells such as pericytes and smooth muscle cells create a microenvironment that affects the behavior of several stem and progenitor cells, in hematological malignancies.

Kidney cancer is a heterogenous disease. This book covers:

-new surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques;
-new staging and prognostic capabilities;
-evolving therapeutic options include, cell based vaccine, gene and antibody therapy;
-molecular genetics allow for a better understanding of the various types of kidney cancer. Kidney Cancer is a comprehensive review covering present and future surgical approaches, staging and prognostic factors, currently accepted and future plans for prevention, diagnosis and treatment. Contributing authors to this book are internationally recognized specialists in this disease. This book will be useful to the specialist (oncologist and urologist), primary care physicians, patients and family members dealing with kidney cancer.

The use of intra-arterial therapy is not nearly as easy as the use of systemic intravenous therapy. The unique complications of intra-arterial therapy can be minimized by selecting the right drug delivery system and by judicious use of appropriate chemotherapeutic agents. Intra-arterial therapy should not be used by physicians who are unwilling to provide the commitment necessary. Experience and dedication are essential ingredients. Only careful clinical investigation can underwrite the future in this area. REFERENCES 1. Ensminger WD, Gyves JW: Regional cancer chemotherapy. Cancer Treat Rep (68):101-115, 1984. 2. Clouse ME, Ahmed R, Ryan RB, Oberfield RA, McCaffrey JA: Complications of long-term transbrachial hepatic arterial infusion chemotherapy. Am J Roentgenol (129):799-803, 1977. 3. Niederhuber JE, Ensminger WD, Gyves JW, Thrall J, Walker S, Cozzi E: Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer (53):1336-1343, 1984. 4. Lokich J, Ensminger W: Ambulatory pump infusion devices for hepatic artery infusion. Sem Onc (10):183-190, 1983.

The early, organ-specific diagnosis of malignancy continues to be a major unmet medical need. Clearly the ability to establish an early diagnosis of cancer is dependent upon an intimate knowledge of the cancer's biology, which if understood at the molecular level should identify key diagnostic and therapeutic manipulation points. Advances in recombinant gene technology have provided significant understanding of the mechanisms of action of oncogenic viruses, as well as of cancer-associated genomic sequences (onco genes). This text will explore the known molecular genetic, biolog ical, and clinical knowledge of selected human neoplasms that demonstrate association with suspected oncogenic virus and those cytogenetic alterations that either cause or are caused by oncogene activation. The text first reviews the cytogenetics of human cancers link ing classical cytogenetics and molecular genetics. Avery A. Sand berg (Roswell Park Memorial Institute, Buffalo, New York) reviews the leukemias and lymphomas, followed by S. Pathak (M. D. Anderson Hospital and Tumor Institute, Houston, Texas), who reviews solid tumors. Functional consideration of oncogenes is highlighted by Keith C. Robbins and Stuart A. Aaronson (NO, Bethesda, Maryland) through their description of the v-sis locus sis and its gene product p.28; a protein that closely resembles human platelet-derived growth factor (PDGF)."

Dry Eyes of Innocence is an extraordinary story of courage and strength in the fight against Leukemia! A chronicle from the author's viewpoint, as he witnesses a personal transformation unfold in the last five or six years of his brothers awe-inspiring battle. Jeffrey was imprisoned from the age of 15 to 37, and then released into a world foreign to him. As an adult, in free society, Jeffrey learned the ropes of true manhood and responsibility and then fell victim to a terminal illness. Growing spiritually and emotionally while withering physically. Jeff and his family ponder -- will a matching donor be found in time? Will the transplant be successfull, or rejected? Will the effects of this physical assault on his body cause him to succumb? Or, will victory reign? The author finds himself in transformation from fear to victory, learning of Jeffrey's Leukemia at the most inopportune time, then helping his big brother overcome some of the most surreal moments of life imaginable. One finger in the air from Jeffrey is the constant reminder of his source of strength. this thug turned darling, with no internal organs and no self-sustaining breath, musters the strength to raise one finger and miraculously sing, "There's not a friend like the lowly Jesus. No, not one.No, not one!" All of the ward nurses and doctors come running to witness this miracle! Dry Eyes of Innocence is a must read for anyone seeking strength in the midst of a storm, anyone searching for power to transform lives and for an inspiring message from an unlikely champion! 6 x 9 trade hard cover - 128 pages

Death receptors play a central role in directing apoptosis in mammalian cells. This process of active cell death is important for a number of biological processes, e.g. for the regulation of the immune system. Death receptors are cell surface receptors that transmit apoptotic signals initiated by corresponding death ligands. Many complex signaling pathways are activated and apoptosis is the final result of a complex biochemical cascade of events.

Besides their role in the induction of cell death, evidence now exists that death receptors are able to activate several non-apoptotic signaling pathways which, depending on cellular context, may lead to apoptosis resistance, secretion of pro-inflammatory proteins, proliferation and invasive growth of cancer cells.

This book looks at the molecular basis of death receptor signaling and the role of death receptors in cancer development.

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Un fortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes that aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up to date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion: first, by dividing the oncology literature into specific subdivisions such as lung can cer, genitourinary cancer, pediatric oncology, etc.; second, by asking emi nent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good indepth reviews of cancer topics, and published symposium lectures are often the best overviews available. Un fortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes which aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, revised frequently to keep the coverage up-to-date, easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion. First, by dividing the oncology literature into specific subdivisions such as lung cancer, genitourinary cancer, pediatric oncology, etc. Second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diagnosis, staging, markers, all forms of treatment modalities, basic biology, and more."

In recent years much progress has been made in knowledge and understanding of the biology of cutaneous melanoma. In this respect etiological factors, prognostic factors, antigen expression of melanoma cells, immune response and mechanisms of metastasis formation have to be mentioned. It is the purpose of this book to give a review on fundamental aspects, diagnosis and prognosis, and treatment of cutaneous melanoma and precursor lesions. Moreover, previously unpublished new data are presented. A post-graduate Boerhaave course "Cutaneous Melanoma and Precursor Lesions" was held at Leiden University on 12 and 13 April, . 1984. The proceedings are contained in this volume. The editors would like to thank all speakers and chairpersons on the course, the Boerhaave Committee for its contribution to the organisation of the course, Upjohn Nederland for its financial support and Mrs. I.A. Kruyff for her secretarial assistance. Dirk Ruiter, Kees Welvaart and Soldano Ferrone, Leiden and Valhalla (NY), June, 1984. VII CONTENTS Preface v Contents VII List of First Authors with Co-Authors XI PART I: FUNDAMENTAL ASPECTS. The epidemiology of melanoma R.M. MACKIE The molecular biology of carcinogenesis 9 A.W.M. VAN DER KAMP AND N.G.J. JASPERS 19 Human melanoma associated antigens identified with monoclonal antibodies: characterization and potential clinical application P.G. NATALI, R. CAVLIERE, M. MATSUI, G. BURAGGI, L. CALLEGARO, and S. FERRONE Cellular and molecular parameters of tumor progression in 38 human malignant melanoma J. BRUEGGEN, E.B. BROECKER, L. SUTER, K. REDMANN, and C.

During the course of editing 'Supportive Care in Cancer Therapy' (Martin us Nijhoff Publishers, 1983), it become apparent that several topics would have to await a second volume. Furthermore, development of new informa tion and evolution of ideas continues. This volume continues the intent of the first to present reviews of issues relating to supportive care, and to identify areas where further definition and further research is needed. The physician reading this volume will find the contents though-provok ing. In addition to reviews authored by physicians, there are chapters authored by non-physicians, who present a different perspective and a dif ferent style of writing. Reverend Bigler writes from his long experience as a chaplain for cancer patients, and tries to identify the changes that take place in the personality of the chaplain who works with dying patients. Ms. Kil lion and Ms. Powell try to describe what an Oncology Nurse is, rather than what one does. Attorneys Reese and Price present a very practical summa tion of issues which face the cancer patient, and their chapter could easily be copied and offered to one's patients; furthermore, this chapter gives direc tion to the physician who is frequently called upon for advice regarding issues which lie entirely outside his/her formal training. Excellent reviews on more' medical' subjects are here. 'Cancer in the Elderly' should provoke oncologists to re-examine their approach to the geriatric patient."

This book has been well received in many places and in many countries. It was awarded a ranking in the top ten publications on behavioral medicine in the year that it first appeared. When, in 1977, we began to fit the components of Cancer, Stress, and Death together, the established medical view was that each subject repre sented a different discipline, and that to integrate fields so diverse in information content was to seek to achieve a synthesis beyond reasonable limits. Had we been required to concern ourselves with the knowledge of each component in its entirety, this might have been so, but our concern, of course, was to integrate only those items of knowledge in any one field that could bear upon the field of interest of another. Moreover, we were concerned that physi cians and scientists take account of the inner forces that shape motivation and individual behavior, as well as the cultural identity of individuals, and we hoped that the biopsychosocial way in which we believed would gain ground and win support. Now, with need for a second edition, one can hardly conceive of not bringing together diverse contributions in one volume. Such syntheses as we have made clearly confirm that one can arrive at several levels of understanding of human situations through wise integration of biological paradigms within various social, cultural, and psychological parameters-which essentially is a simple way of defining the biopsychosocial way."

Protein kinase C (PKC), a family of serine-threonine kinases, rocketed to the forefront of the cancer research field in the early 1980's with its identification as an effector of phorbol esters, natural products with tumor promoting activity. Phorbol esters had long been of interest to the cancer research field due to early studies in the mouse skin carcinogenesis model, which showed that prolonged topical application of phorbol esters promoted the formation of skin tumors on mice previously treated with mutagenic agents. Research in the last years has established key roles for PKC isozymes in the control of cell proliferation, migration, adhesion, and malignant transformation. In addition, there is a large body of evidence linking PKC to invasion and cancer cell metastasis. Moreover, it is now well established that the expression of PKC isozymes is altered in various types of cancers. More importantly, small molecule inhibitors have been developed with significant anti-cancer activity. The relevance of PKC isozymes in cancer signaling is therefore remarkable. This book will have 4 sections. There will be 23 chapters. Each section will have a brief introduction by an expert in the field (~ 1-2 pages).

This multidisciplinary reference explores the concepts and realities of quality of life among cancer survivors in its physical, psychological, cognitive, social, and familial dimensions. Informed by a broad range of fields including genetics, psychiatry, nursing, dentistry, rehabilitation, and ethics, it addresses daily challenges of living for this population, from self-care to cultural concerns and from social interactions to experiences with providers. Family issues of pediatric, young adult, and elder survivors, caregiving parents, and siblings are a major area of concern. And contributors describe interventions for survivors as individuals, in family content, and as part of integrated care across primary and specialty settings. Included among the topics: Play, leisure activities, and cognitive health among older cancer survivors. Genetic mutations in cancer susceptibility genes: a family history of cancer. Cancer patients in a pediatric intensive care unit: a single center experience. The impact of childhood cancer on the quality of life among healthy siblings. When cancer returns: family caregivers and the hospice team. Experiencing cancer services: a story of survival and dissatisfaction. A significant addition to the cancer survivorship literature, Quality of Life Among Cancer Survivors is a practice-building resource for oncology and allied health professionals, health psychologists, and social workers, as well as researchers in these fields.

Oncofertility integrates the two previously distinct fields of cancer treatment and fertility research and aims to explore and expand the reproductive future of cancer survivors. In order to achieve the goal of fertility preservation, the Oncofertility community must focus on communication and the way data is provided and received. Concomitant with the rapidly changing technology of Oncofertility, there have been radical shifts and advances in the way health educators and clinicians can produce and share information.As success rates of reproductive techniques such as egg freezing and banking continue to rise, providing increasing opportunities for young cancer patients to preserve their fertility prior to the onset of cancer treatments, communication among professionals in oncology, reproductive medicine, and psychosocial work, among others, becomes crucial, and clinical demand for Oncofertility information is expected to rise considerably.

"Oncofertility Communication" describes and addresses the myriad channels through which the multiple audiences involved in Oncofertility can be served with appropriate and accurate information about cancer-related fertility issues. The text answers frequently asked questions and provides invaluable insights to scientific and health care professionals about communication among the diverse Oncofertility audiences. It incorporates timely discussions about traditional and emerging electronic communication tools and discusses the impact of health care policy changes on the Oncofertility field. "

Statistical methods for clinical trials have been an area of active research in Biostatistics since the first modern clinical trials were mounted in 1946 by the British Medical Research Council in whooping cough and tuberculosis. Often, the participants in clinical trials suffer from potentially fatal chronic diseases, and it is especially important that these experiments in medical research use designs that are efficient, can be understood by physicians, policy makers and patients, respond quickly new ideas in medicine and statistics, and, perhaps above all, show respect for the complex and important ethical issues that arise in these settings. This book explores some recent thinking in designs for clinical trials, including alternative designs for phase I studies, interim monitoring for futility, adaptive designs based on accumulating outcome data, and designs of new, targeted therapies. The book is intended for both the statistical practitioner, who may be too busy to stay abreast of the literature on statistical methods, as well as statisticians conducting research in clinical trials.

Fluorescence is a very powerful tool for work at the frontier of cell biology, photobiology and bioinstrumentation. The stated aim of the workshop was to highlight the significance of fluorescence work for the understanding of cell and tissue physiology, physiopathology and pharmacology, particulary in terms of the analytical use of fluorescent probes in oncology. In the organization of the workshop a multidisciplinary approach was selected. The purpose of the Advanced Research Workshop (ARW) was to bring together researchers in the various disciplines of tissue optics, imaging, microspectrofluorometry and state of the art probes, in order to explore the full benefits that can be derived in biomedicine through the convergence of these approaches. When applied to in vivo and in situ studies, fluorescence and related optical methods enable us to explore within tissues, cells and organelles photon effects previously understood only in solution photochemistry. Processes which can be studied at the molecular level by photophysics, photochemistry and physical chemistry can be evaluated in living tissue by fluorescence spectroscopy and imaging at the intracellular level in terms of structure and function. Thus, fluorescence adds a new dimension to cell biology and physiology. This approach is now supported by a full and versatile, rapidly growing armamentarium of new selective probes for organelles, enzymes, cations, cytoskeleton and metabolic control.